Tim Hirst | CEO
GPN Vaccines

Dr Tim Hirst is the Chairman and CEO of GPN Vaccines (https://gpnvaccines.com) an Australian biotechnology company conducting clinical trials of a new vaccine against the world’s foremost bacterial pathogen, Streptococcus pneumoniae. He is an entrepreneur, investor and internationally acclaimed microbiologist with extensive expertise in the life sciences, executive management and venture capital investment. He was previously CEO of ANU Connect Ventures, a $30M pre-seed VC fund based in Canberra, the Vice President and Deputy Vice Chancellor for Research & Innovation at The University of Sydney and Professor & Head of Microbiology at the University of Bristol, UK. In 2022, TechBoard named him, Australian Angel Investor of the Year. Tim also holds the position of Non-Executive Chairman of Brain Changer Pty Ltd, Flex-G Pty Ltd, Dentroid Pty Ltd and Gamma Vaccines Ltd, and is a Director of PPB Technology Pty Ltd and Griffin Accelerator Holdings Pty Ltd - Canberra's leading business incubator. He is also an Honorary Adjunct Professor at the University of Adelaide.